NY-DILIGENT/INSIGHTIA
11.1.2022 14:02:12 CET | Business Wire | Press release
Diligent , the global leader in modern governance providing SaaS solutions across governance, risk, compliance and ESG, today announced that it has acquired Insightia, a leading SaaS provider of expert insights and intelligent analytics for listed companies, with a focus on shareholder activism, proxy voting and corporate governance. Financial terms of the transaction were not disclosed.
Formed from the 2020 merger of Activist Insight and Proxy Insight, Insightia offers a single source of global public company information to a range of global investment banks, law firms, proxy solicitors, and other corporate advisors. Representative clients include PJT CamberView, Glass Lewis, Morrow Sodali, FTI Consulting, and Georgeson.
Bringing together Diligent’s leading governance, analytics and ESG solutions with Insightia’s vital intelligence across a variety of public company data will provide clients with even more meaningful insights to power their board and organizations’ governance practices. Clients will have access to a rich ecosystem of organizational risk assessments and data tools in areas spanning board composition, executive compensation, supply chain due diligence, and ESG standards and frameworks. Diligent will also pursue a range of potential solution integrations with Insightia, including adding activist investor alerts within its Boards application, enabling clients to better monitor susceptibility to activism.
Brian Stafford, CEO of Diligent, said: “From our regular interactions with board members, business leaders and investors, we understand that having access to the most comprehensive and relevant data facilitates better guidance and confident decision-making. That is why we are so pleased to bring onboard Insightia’s deep experience and market-leading intelligent analytics, particularly against the backdrop of a marketplace where shareholder engagement is rapidly evolving. Current and future clients can look forward to even more insights on the issues that matter most so that they can continue to build successful, equitable and sustainable organizations.”
Kerry Pogue, Co-Founder and CEO of Insightia, said: “We are excited to benefit from Diligent’s expertise and resources as a leading SaaS organization in this next phase of Insightia’s growth journey. Combining our capabilities with Diligent’s governance, analytics and ESG solutions is a compelling next step as we look to scale our offerings globally for the benefit of our clients. Both companies are incredibly complementary in terms of their strategy and culture, and our team looks forward to being part of Diligent and accelerating the reach of our mission.”
District Capital Partners served as the exclusive financial advisor, and Willkie Farr & Gallagher LLP served as the legal advisor to Diligent. Taylor Wessing served as the legal advisor to Insightia.
About Diligent Corporation
Diligent is the global leader in modern governance providing SaaS solutions across governance, risk, compliance and ESG to over 1 million users from over 25,000 customers around the world. Our innovative technology gives leaders a connected view of governance, risk, compliance and ESG across their organizations, sparking the insights they need to make better decisions and lead with purpose. Learn more at diligent.com .
About Insightia
Headquartered in London, Insightia was formed in 2020 through the merger of Activist Insight and Proxy Insight, who together have provided a variety of shareholder activism, shareholder voting, and corporate governance data to a global client base for the past decade. Insightia’s mission is to improve engagement, stewardship and corporate governance through the delivery of timely intelligence to key stakeholders and their advisors. Learn more at insightia.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220111005384/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom